These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 14505898)

  • 1. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccine (dTpa) administered as a booster to 4-6 year-old children primed with four doses of whole-cell pertussis vaccine.
    Kosuwon P; Warachit B; Hutagalung Y; Borkird T; Kosalaraksa P; Bock HL; Poovorawan Y
    Vaccine; 2003 Oct; 21(27-30):4194-200. PubMed ID: 14505898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reactogenicity and immunogenicity of reduced antigen content diphtheria-tetanus-acellular pertussis vaccines as a booster in 4-7-year-old children primed with diphtheria-tetanus-whole cell pertussis vaccine before 2 years of age.
    Dagan R; Igbaria K; Piglansky L; Van Brusteghem F; Melot V; Kaufhold A
    Vaccine; 1999 Jun; 17(20-21):2620-7. PubMed ID: 10418911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative trial to assess the reactogenicity of the diphtheria-tetanus-acellular pertussis (DTPa) vaccine plus Haemophilus influenzae type B (Hib) conjugate vaccine and that of the diphtheria-tetanus-whole cell pertussis (DTPw) vaccine plus Hib conjugate vaccine, administered in single injection a.
    Calbo F; Dal-Ré R; Díez-Delgado J; Oña S; Sánchez-Prados F; García-Corbeira P;
    Med Clin (Barc); 2002 Jan; 118(1):1-4. PubMed ID: 11803003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acellular pertussis diphtheria-tetanus-pertussis vaccine containing separately purified pertussis toxoid, filamentous haemagglutinin and 69 kDa outer membrane protein as a booster in children.
    Kanra G; Ceyhan M; Vandevoorde D; Bogaerts H
    Eur J Pediatr; 1993 Jun; 152(6):478-83. PubMed ID: 8335014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
    Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
    Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
    Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
    Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, reactogenicity and safety of three-dose primary and booster vaccination with combined diphtheria-tetanus-whole-cell pertussis-hepatitis B-reduced antigen content Haemophilus influenzae type b vaccine in Filipino children.
    Gatchalian SR; Ramakrishnan G; Bock HL; Lefevre I; Jacquet JM
    Hum Vaccin; 2010 Aug; 6(8):664-72. PubMed ID: 20657177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised controlled trial with a diphtheria-tetanus-acellular pertussis (dTpa) vaccine in adults.
    Van der Wielen M; Van Damme P; Joossens E; François G; Meurice F; Ramalho A
    Vaccine; 2000 Apr; 18(20):2075-82. PubMed ID: 10715521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety and immunogenicity of a booster dose of an acellular pertussis vaccine containing a genetically inactivated pertussis toxin in fifteen- to twenty-one-month-old children. Italian Multicenter Group for the Study of Recombinant Acellular Pertussis Vaccine.
    Podda A; Bona G; Canciani G; Pistilli AM; Contu B; Furlan R; Meloni T; Stramare D; Titone L; Rappuoli R
    J Pediatr; 1995 Aug; 127(2):238-43. PubMed ID: 7636648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a fifth dose of a five-component acellular or a whole cell pertussis vaccine in children four to six years of age.
    Halperin SA; Scheifele D; Barreto L; Pim C; Guasparini R; Medd L; Meekison W; Eastwood BJ
    Pediatr Infect Dis J; 1999 Sep; 18(9):772-9. PubMed ID: 10493336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
    Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
    Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of a reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine as a single-dose booster in Singaporean adults.
    Chan SH; Tan PT; Han HH; Bock HL
    Singapore Med J; 2006 Apr; 47(4):286-90. PubMed ID: 16572239
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children.
    Pichichero ME; Deloria MA; Rennels MB; Anderson EL; Edwards KM; Decker MD; Englund JA; Steinhoff MC; Deforest A; Meade BD
    Pediatrics; 1997 Nov; 100(5):772-88. PubMed ID: 9346976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acellular vaccines containing reduced quantities of pertussis antigens as a booster in adolescents.
    Tran Minh NN; He Q; Ramalho A; Kaufhold A; Viljanen MK; Arvilommi H; Mertsola J
    Pediatrics; 1999 Dec; 104(6):e70. PubMed ID: 10586004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen-content dTpa-IPV vaccine.
    Sänger R; Behre U; Krause KH; Loch HP; Soemantri P; Herrmann D; Schmitz-Hauss E; Wolter J; Hoet B
    Eur J Pediatr; 2007 Dec; 166(12):1229-36. PubMed ID: 17235521
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of six acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fifth dose in four- to six-year-old children.
    Pichichero ME; Edwards KM; Anderson EL; Rennels MB; Englund JA; Yerg DE; Blackwelder WC; Jansen DL; Meade BD
    Pediatrics; 2000 Jan; 105(1):e11. PubMed ID: 10617748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decennial administration in young adults of a reduced-antigen content diphtheria, tetanus, acellular pertussis vaccine containing two different concentrations of aluminium.
    Vandermeulen C; Theeten H; Rathi N; Kuriyakose S; Han HH; Sokal E; Hoppenbrouwers K; Van Damme P
    Vaccine; 2015 Jun; 33(26):3026-34. PubMed ID: 25613716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.
    Silfverdal SA; Assudani D; Kuriyakose S; Van Der Meeren O
    Hum Vaccin Immunother; 2014; 10(10):2795-8. PubMed ID: 25483640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of combined diphtheria-tetanus-pertussis (whole cell and acellular)-Haemophilus influenzae-b conjugate vaccines administered to Indonesian children.
    Richie E; Punjabi NH; Harjanto SJ; Wangsasaputral F; Sukandar M; Supriatman M; Simanjuntak CH; Que JU; Cryz SJ
    Vaccine; 1999 Mar; 17(11-12):1384-93. PubMed ID: 10195774
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactogenicity and immunogenicity at preschool age of a booster dose of two three-component diphtheria-tetanus-acellular pertussis vaccines in children primed in infancy with acellular vaccines.
    Tozzi AE; Anemona A; Stefanelli P; Salmaso S; Ciofi degli Atti ML; Mastrantonio P; Giammanco A;
    Pediatrics; 2001 Feb; 107(2):E25. PubMed ID: 11158499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.